Do Latest SURPASS Findings With Twincretin in Diabetes Impress?
Published on: Thursday 10 February 2022
SURPASS-5 is latest published trial of a novel investigational once-weekly twincretin drug; editorialist says it leaves a number of unanswered questions about how best to use tirzepatide, if approved.
News source: https://www.medscape.com/viewarticle/968251
